Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study

Ejemplares similares

• Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes
  por: Kathrine Kold Sørensen, et al.
  Publicado: (2026)
• Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
  por: Estela Lajthia
  Publicado: (2019)
• Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
  por: Richard J. MacIsaac, et al.
  Publicado: (2024)
• An efficient stability criterion for process control systems based on numerical computation of matrix square root with predefined accuracy
  por: Hooman Fatoorehchi, et al.
  Publicado: (2026)
• Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
  por: Natalia Andrea Rojas-Henao
  Publicado: (2018)